Enzyme Replacement Therapy Market
Enzyme Replacement Therapy Market by Therapeutic Condition, Route of Administration, Distribution Channel & Region - Forecast 2022 - 2028
Market Insights on Enzyme Replacement Therapy covering sales outlook, demand forecast and up-to-date key trends
Enzyme Replacement Therapy Market Outlook (2022-2028)
[305 Pages Report] The global enzyme replacement therapy market is expected to be worth US$ 9.3 Billion in 2022, with a CAGR of 6.7% to reach US$ 13.8 Billion by the end of 2028. Enzyme replacement therapy (ERT) revenue accounts for approximately 63% of the global hormone replacement market. The increased incidence of rare diseases has majorly contributed to the use of enzyme replacement therapies, and medical research is expected to accelerate this progress further. According to Future Market Insights, the market of enzyme replacement therapy is attributed to the below-mentioned reasons:
- The increase in BPS values is connected to increased research into rare disease avenues as well as the innovation of orphan drug delivery systems.
- The recent increase in the occurrence of rare and ultra-rare diseases.
- An increase in the number of rare diseases that require novel treatment approaches, an increase in the availability of enzyme replacement therapies, increased awareness, and less stringent regulations for rare disease treatment.
- Expanding medical research and public awareness about enzyme replacement therapies.
The COVID-19 pandemic entirely changed the way the world viewed healthcare, resulting in significant developments and shifts in the medical industry. Coronavirus diseases spread rapidly throughout the world, reinventing healthcare systems worldwide. Countries went into complete lockdown, and many essential activities and operations ceased abruptly, causing markets to halt.
The ERT industry was also affected by the abrupt closure of supply and demand chains around the world. Due to global lockdown restrictions, the enzyme replacement therapy market also suffered a detrimental effect on research and development.
|
Enzyme Replacement Therapy Market Size (2022) |
US$ 9.3 Bn |
|
Revenue Estimation (2028) |
US$ 13.8 Bn |
|
Global Market Growth Rate (2022-2028) |
6.7% CAGR |
|
North America Market Share |
28.6% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Market Growth to Ride on Elevating Demand in North America and Europe
North America's enzyme replacement therapy industry offers a dominant market share of 28.6% in 2022, leading the global market landscape. This region is anticipated to be one of the greatest lucrative businesses for enzyme replacement therapy, with rising healthcare spending driving ERT demand. The United States is projected to lead the industry of enzyme replacement therapy in North America.
Western Europe's enzyme replacement therapy market is following closely. The region has witnessed a substantial increase in rare disease cases in recent years, which has induced the growth of enzyme replacement therapy demand. Both Germany and the Kingdom, for example, have a higher prevalence of Fabry's disease and other chronic illnesses, which drives demand for enzyme replacement therapy. The sheer volume of MPS and SCID patients is one of the factors driving market growth in the European region.
Key players to bolster the growth by upgrading Products and Technology
The market has a large number of both global and local players. The vast bulk of these market participants is well-known for their portfolio of inherited metabolic diseases, making treatment simple and effective.
Shire Plc, Sanofi S.A., AbbVie, and Allergan plc, for example, have a strong presence worldwide in terms of a supply chain network and operating facilities. Key players are primarily concerned with developing and marketing drugs for rare and genetic diseases. For example, Shire, plc has over 40 products sold globally that are solely focused on rare and orphan diseases. The manufacturer is also committed to raising awareness about these diseases and, as a result, is constantly launching new campaigns to increase awareness.
In addition, major players are pursuing mergers, acquisitions, and strategic alliances, which are predicted to propel the enzyme replacement therapy market. The majority of the firms are concentrating on the creation of new items. Diverse companies are also entailed in the licensing and distribution of drugs in order to better assist patients.
Revenue from enzyme replacement therapy (ERT) accounts for around 63% share of the global hormone replacement market. Increasing prevalence of rare diseases has majorly led to the deployment of enzyme replacement therapies, and medical research is expected to further advance these developments.
Find your sweet spots for generating winning opportunities in this market.
How The Market Progressed Till June 2022?
|
Particulars |
Details |
|
H1, 2021 |
6.52% |
|
H1, 2022 Projected |
6.66% |
|
H1, 2022 Outlook |
6.56% |
|
BPS Change - H1, 2022 (O) – H1, 2022 (P) |
(-) 10 ↓ |
|
BPS Change – H1, 2022 (O) – H1, 2021 |
(+) 04 ↑ |
The comparative analysis and market growth rate of global enzyme replacement therapy market as studied by Future Market Insights, will show a negative BPS growth in H1-2022 outlook as compared to H1-2022 projected period by 10 BPS, and, a surge in BPS values is expected in H1-2022 over H1- 2021 duration with only 04 Basis Point Share (BPS).
The global enzyme replacement therapy market is subject to external funding and grants for development of products, and reimbursement guidelines for specified therapies.
The key developments in the market include development of treatments for rare diseases, encapsulation of enzymes to enhance stability, and growing studies to utilize virosomes for enzyme delivery. The market is highly influenced by the high treatment costs, prevalence of disease, and the anatomical side effects associated with the therapy.
The market decline observed through the drop in the BPS values is addressed by the short in-vivo half-life of the enzymes, lack of targeted action and tissue specificity, and patient immune system reaction against the enzyme.
Conversely, the spike in BPS values is associated with the growing research within rare disease avenues as well as the development of orphan drug delivery systems. Moreover, the efficacy of enzyme replacement therapies have further promoted their adoption, thus assisting with the growing market values.
Enzyme Replacement Therapy Demand Analysis (2013 to 2021) Vs Market Predictions (2022 to 2028)
The enzyme replacement therapy market is expected to flourish over the coming years as instances of rare and unknown diseases increase on a global scale. There has been a surge in the emergence of rare and ultra-rare diseases over the past few years, and this trend is not expected to slow down anytime soon. The need for orphan disease management and orphan drugs has seen a substantial increase as rare diseases have become more frequent.
Enzyme replacement therapy demand increased at a CAGR of 6.4% from 2013 to 2021 and ended up with a value of US$ 8.8 Bn in 2021. Increasing instances of rare diseases that require unique treatment approaches, rising availability of enzyme replacement therapies, increasing awareness, and less tough regulations for rare disease treatment are primarily driving demand for ERT.
Increasing medical research and rising awareness about enzyme replacement therapies are expected to be common factors propelling ERT market growth across the world.
All in all, the global enzyme replacement therapy market is predicted to progress at a CAGR of 6.7% from 2022 to 2028.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Which Region is Most Lucrative for Enzyme Replacement Therapy Providers?
This enzyme replacement therapy industry survey by FMI covers market statistics on a global scale, and especially gives metrics specific to regions such as North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa (MEA).
Leading the global market landscape, the North America enzyme replacement therapy market holds a dominant market share of 28.6% in 2022.
This region is expected to be one of the most lucrative markets for enzyme replacement treatment, and ERT demand is expected to be driven by rising healthcare expenditure in the region. The U.S. is expected to lead the North American enzyme replacement therapy industry.
Following closely is the Western Europe enzyme replacement therapy market. The region, over the past few years, has experienced tremendous increase in rare disease instances, and this has influentially shaped the enzyme replacement therapy demand growth.
For instance, Germany and the U.K. have a high incidence of Fabry’s disease and other rare diseases as well that drives demand for enzyme replacement therapy.
East Asia, South Asia, and the Pacific regions are expected to exhibit lucrative opportunities for enzyme replacement therapy providers over the coming years.
Rising disposable income, developing healthcare systems, increasing awareness are major factors influencing the enzyme replacement therapy market potential in these regions. Japan, India, and China are expected to be leading nations in these regions.
Demand for enzyme replacement treatment in MEA is anticipated to rise at a steady pace over the forecast period; the region currently holds around 3% of the global market share.
Country-wise Analysis
What’s Driving Demand for Enzyme Replacement Therapy in Japan?
Japan is one of the most technologically advanced nations in the world and has an advanced healthcare system to accommodate the nation’s healthcare needs in the most efficient manner possible. Advancements in the medical research field in Japan are expected to propel enzyme replacement therapy market growth majorly in the nation.
Apart from this, growing geriatric population and increasing incidence of rare diseases are also anticipated to complement enzyme replacement therapy demand over the forecast period. Japan accounts for nearly 23% share of the global enzyme replacement therapy market in terms of volume, at present.
How Can Enzyme Replacement Therapy Providers Maximize their Revenue Potential in the U.S.?
The U.S. is one of the most important healthcare markets of the world and also one of the most advanced ones. Enzyme replacement therapy solution providers can target this nation to take advantage of the advanced and developed healthcare infrastructure that provides a lucrative setting for major medical research breakthroughs and promotes novel drug development practices.
Adoption of advanced and innovative technologies, presence of leading ERT providers, and increasing investments in medical research & development are some other factors driving demand for enzyme replacement therapy in the U.S.
Leading as well as new enzyme replacement therapy providers can target this market to make their mark in the global industry landscape and further establish themselves.
Category-wise Analysis
Which Route of Administration for ERT is Expected to Hold Highest Share?
Administration of enzyme replacement therapy is majorly through oral or injectable means, and of these two, injectable ERT is expected to lead the global market in terms of share over the forecast period. Increase in demand for injectable ERT drugs is expected to majorly drive the injectable segment to domination over the coming years.
Injectable ERT is predicted to account for more than 80% of the global enzyme replacement therapy market while accounting for major revenue generation opportunities.
COVID-19 Crisis Analysis
The COVID-19 pandemic completely changed the way the world approached healthcare and led to some major changes and advancements in the medical industry. Coronavirus infections spread rampantly throughout the world and revolutionized the healthcare systems across the world. Countries went into a complete lockdowns and many essential activities and operations stopped abruptly and halted markets.
The ERT industry was also disrupted due to the abrupt shutdown of supply and demand chains across the world. The enzyme replacement therapy market also saw a negative impact on the research and development aspect due to lockdown restrictions across the world.
But this has changed and is expected to change further in the post-pandemic era as the world returns to normalcy and research & development related to enzyme replacement therapy pick up pace.
Competitive Landscape
Enzyme replacement therapy providers are focusing on medical research & development to develop effective treatments for various rare diseases. Companies developing enzyme replacement therapies can target regions where instances of rare diseases are frequent and rising.
- In August 2021, the U.S. Food and Drug Administration (FDA) approved the use of Nexviazyme (avalglucosidase alfa-ngpt) for the treatment of Pompe disease. The approved drug would be used in the treatment of patients of one year of age or older with late-onset Pompe disease. It is an enzyme deficiency that leads to the accumulation of complex sugar called glycogen in skeletal and heart muscles, and is a rare disease.
- In May 2021, Aceragen, a biopharmaceutical firm focused on transformational therapeutics, announced the acquisition of Enzyvant’s RVT-801 (now ACG-801). It is an investigational enzyme replacement therapy for ceramidase deficiency presenting itself as Farber disease for which no disease-specific therapy is present.
Enzyme Replacement Therapy Industry Report Scope
|
Attribute |
Details |
|
Forecast Period |
2022-2028 |
|
Historical Data Available for |
2013-2021 |
|
Market Analysis |
US$ Mn for Value |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Pricing |
Available upon Request |
Key Segments of Enzyme Replacement Therapy Industry Survey
Enzyme Replacement Therapy Market by Therapeutic Condition:
- Enzyme Replacement Therapy for Fabry Disease
- Enzyme Replacement Therapy for Gaucher Disease
- Enzyme Replacement Therapy for Mucopolysaccharidosis
- MPS I
- MPS II (Hunter Syndrome)
- MPS IVA (Morquio Syndrome, Type A)
- MPS VI (Maroteaux-Lamy Syndrome)
- MPS VII (Sly Syndrome)
- Enzyme Replacement Therapy for Pompe Disease
- Enzyme Replacement Therapy for Lysosomal Acid Lipase Deficiency
- Others
Enzyme Replacement Therapy Market by Route of Administration:
- Oral Enzyme Replacement Therapy
- Injectable Enzyme Replacement Therapy
Enzyme Replacement Therapy Market by Distribution Channel:
- Hospital Pharmacies
- Specialty Treatment Pharmacies
- Retail Pharmacies
Enzyme Replacement Therapy Market by Region:
- North America Enzyme Replacement Therapy Market
- Latin America Enzyme Replacement Therapy Market
- Europe Enzyme Replacement Therapy Market
- East Asia Enzyme Replacement Therapy Market
- South Asia & Pacific Enzyme Replacement Therapy Market
- Middle East & Africa (MEA) Enzyme Replacement Therapy Market
Frequently Asked Questions
What is the Enzyme Replacement Therapy Market CAGR through 2028?
The enzyme replacement therapy market is expected to capture a CAGR of 6.7% through 2028.
What was the Historical Performance of the Enzyme Replacement Therapy Market?
The market's historical performance was positive, with a CAGR of 6.4% from 2013 to 2021.
Which are the Top Three Countries Leading the Enzyme Replacement Therapy Market?
North America, Europe, and Asia Pacific are the top 3 countries leading the market.
Which Product Type Dominates the Enzyme Replacement Therapy Market?
Injectable enzyme replacement therapy is the dominant product type in the enzyme replacement therapy market
Why is Asia Pacific’s Enzyme Replacement Therapy Market Expanding Remarkably?
Rising disposable income and increasing awareness are the factors expanding Asia Pacific’s market remarkably.
Table of Content
1. Executive Summary 1.1. Market Overview 1.2. Market Analysis 1.3. FMI Analysis and Recommendations 1.4. Wheel of Fortune 2. Market Introduction 2.1. Market Taxonomy 2.2. Market Definition 3. Market View Point Analysis 3.1. Macro-Economic Factors 3.2. Market Dynamics 3.2.1. Drivers 3.2.2. Restraints 3.2.3. Trends 3.3. Opportunity Analysis 3.4. Value Chain Analysis 4. Macroeconomic Assumptions 5. Global Economic Outlook 5.1. Gross Domestic Product by Region & Country, 2006 – 2021 5.2. Global Pharmaceutical Market Outlook 6. Key Inclusions 6.1. Rare Disease Framework 6.2. Orphan Drug Key Regulations, By Country 6.3. Pipeline Assessment of Enzyme Replacement Therapy 7. North America Market Analysis 2013-2021 and Forecast 2022-2028 7.1. Introduction 7.2. Regional Market Trends 7.3. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021 7.3.1. U.S. 7.3.2. Canada 7.4. Market Size (US$ Mn) Forecast By Country, 2022-2028 7.5. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2021 7.5.1. Fabry Disease 7.5.2. Gaucher Disease 7.5.3. Mucopolysaccharidosis 7.5.3.1. MPS I 7.5.3.2. MPS II (Hunter syndrome) 7.5.3.3. MPS IVA (Morquio syndrome, type A) 7.5.3.4. MPS VI (Maroteaux-Lamy syndrome) 7.5.3.5. MPS VII (Sly syndrome) 7.5.4. Pompe Disease 7.5.5. Lysosomal acid lipase Deficiency 7.5.6. Others 7.6. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2022-2028 7.7. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021 7.7.1. Oral 7.7.2. Injectable 7.8. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028 7.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 7.9.1. Hospital Pharmacies 7.9.2. Specialty Treatment Pharmacies 7.9.3. Retail Pharmacies 7.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028 7.11. Market Attractiveness Analysis 7.11.1. By Country 7.11.2. By Therapeutic Condition 7.11.3. By Route of Administration 7.11.4. By Distribution Channel 7.12. Drivers and Restraints: Impact Analysis 7.13. Key Market Participants – Intensity Mapping 8. Latin America Market Analysis 2013-2021 and Forecast 2022-2028 8.1. Introduction 8.2. Regional Market Trends 8.3. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021 8.3.1. Brazil 8.3.2. Mexico 8.3.3. Rest of Latin America 8.4. Market Size (US$ Mn) Forecast By Country, 2022-2028 8.5. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2021 8.5.1. Fabry Disease 8.5.2. Gaucher Disease 8.5.3. Mucopolysaccharidosis 8.5.3.1. MPS I 8.5.3.2. MPS II (Hunter syndrome) 8.5.3.3. MPS IVA (Morquio syndrome, type A) 8.5.3.4. MPS VI (Maroteaux-Lamy syndrome) 8.5.3.5. MPS VII (Sly syndrome) 8.5.4. Pompe Disease 8.5.5. Lysosomal acid lipase Deficiency 8.5.6. Others 8.6. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2022-2028 8.7. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021 8.7.1. Oral 8.7.2. Injectable 8.8. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028 8.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 8.9.1. Hospital Pharmacies 8.9.2. Specialty Treatment Pharmacies 8.9.3. Retail Pharmacies 8.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028 8.11. Market Attractiveness Analysis 8.11.1. By Country 8.11.2. By Therapeutic Condition 8.11.3. By Route of Administration 8.11.4. By Distribution Channel 8.12. Drivers and Restraints: Impact Analysis 8.13. Key Market Participants – Intensity Mapping 9. Western Europe Market Analysis 2013-2021 and Forecast 2022-2028 9.1. Introduction 9.2. Regional Market Trends 9.3. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021 9.3.1. Germany 9.3.2. U.K 9.3.3. France 9.3.4. Italy 9.3.5. Spain 9.3.6. Rest of Western Europe 9.4. Market Size (US$ Mn) Forecast By Country, 2022-2028 9.5. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2021 9.5.1. Fabry Disease 9.5.2. Gaucher Disease 9.5.3. Mucopolysaccharidosis 9.5.3.1. MPS I 9.5.3.2. MPS II (Hunter syndrome) 9.5.3.3. MPS IVA (Morquio syndrome, type A) 9.5.3.4. MPS VI (Maroteaux-Lamy syndrome) 9.5.3.5. MPS VII (Sly syndrome) 9.5.4. Pompe Disease 9.5.5. Lysosomal acid lipase Deficiency 9.5.6. Others 9.6. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2022-2028 9.7. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021 9.7.1. Oral 9.7.2. Injectable 9.8. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028 9.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 9.9.1. Hospital Pharmacies 9.9.2. Specialty Treatment Pharmacies 9.9.3. Retail Pharmacies 9.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028 9.11. Market Attractiveness Analysis 9.11.1. By Country 9.11.2. By Therapeutic Condition 9.11.3. By Route of Administration 9.11.4. By Distribution Channel 9.12. Drivers and Restraints: Impact Analysis 9.13. Key Market Participants – Intensity Mapping 10. Eastern Europe Market Analysis 2013-2021 and Forecast 2022-2028 10.1. Introduction 10.2. Regional Market Trends 10.3. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021 10.3.1. Russia 10.3.2. Poland 10.3.3. Rest of Eastern Europe 10.4. Market Size (US$ Mn) Forecast By Country, 2022-2028 10.5. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2021 10.5.1. Fabry Disease 10.5.2. Gaucher Disease 10.5.3. Mucopolysaccharidosis 10.5.3.1. MPS I 10.5.3.2. MPS II (Hunter syndrome) 10.5.3.3. MPS IVA (Morquio syndrome, type A) 10.5.3.4. MPS VI (Maroteaux-Lamy syndrome) 10.5.3.5. MPS VII (Sly syndrome) 10.5.4. Pompe Disease 10.5.5. Lysosomal acid lipase Deficiency 10.5.6. Others 10.6. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2022-2028 10.7. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021 10.7.1. Oral 10.7.2. Injectable 10.8. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028 10.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 10.9.1. Hospital Pharmacies 10.9.2. Specialty Treatment Pharmacies 10.9.3. Retail Pharmacies 10.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028 10.11. Market Attractiveness Analysis 10.11.1. By Country 10.11.2. By Therapeutic Condition 10.11.3. By Route of Administration 10.11.4. By Distribution Channel 10.12. Drivers and Restraints: Impact Analysis 10.13. Key Market Participants – Intensity Mapping 11. Asia Pacific Excluding China & Japan Market Analysis 2013-2021 and Forecast 2022-2028 11.1. Introduction 11.2. Regional Market Trends 11.3. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021 11.3.1. India 11.3.2. Australia and New Zealand 11.3.3. ASEAN 11.3.4. Rest of APECJ 11.4. Market Size (US$ Mn) Forecast By Country, 2022-2028 11.5. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2021 11.5.1. Fabry Disease 11.5.2. Gaucher Disease 11.5.3. Mucopolysaccharidosis 11.5.3.1. MPS I 11.5.3.2. MPS II (Hunter syndrome) 11.5.3.3. MPS IVA (Morquio syndrome, type A) 11.5.3.4. MPS VI (Maroteaux-Lamy syndrome) 11.5.3.5. MPS VII (Sly syndrome) 11.5.4. Pompe Disease 11.5.5. Lysosomal acid lipase Deficiency 11.5.6. Others 11.6. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2022-2028 11.7. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021 11.7.1. Oral 11.7.2. Injectable 11.8. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028 11.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 11.9.1. Hospital Pharmacies 11.9.2. Specialty Treatment Pharmacies 11.9.3. Retail Pharmacies 11.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028 11.11. Market Attractiveness Analysis 11.11.1. By Country 11.11.2. By Therapeutic Condition 11.11.3. By Route of Administration 11.11.4. By Distribution Channel 11.12. Drivers and Restraints: Impact Analysis 11.13. Key Market Participants – Intensity Mapping 12. China Market Analysis 2013-2021 and Forecast 2022-2028 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2021 12.2.1. Fabry Disease 12.2.2. Gaucher Disease 12.2.3. Mucopolysaccharidosis 12.2.3.1. MPS I 12.2.3.2. MPS II (Hunter syndrome) 12.2.3.3. MPS IVA (Morquio syndrome, type A) 12.2.3.4. MPS VI (Maroteaux-Lamy syndrome) 12.2.3.5. MPS VII (Sly syndrome) 12.2.4. Pompe Disease 12.2.5. Lysosomal acid lipase Deficiency 12.2.6. Others 12.3. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2022-2028 12.4. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021 12.4.1. Oral 12.4.2. Injectable 12.5. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028 12.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 12.6.1. Hospital Pharmacies 12.6.2. Specialty Treatment Pharmacies 12.6.3. Retail Pharmacies 12.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028 12.8. Market Attractiveness Analysis 12.8.1. By Therapeutic Condition 12.8.2. By Route of Administration 12.8.3. By Distribution Channel 12.9. Drivers and Restraints: Impact Analysis 12.10. Key Market Participants – Intensity Mapping 13. Japan Market Analysis 2013-2021 and Forecast 2022-2028 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2021 13.2.1. Fabry Disease 13.2.2. Gaucher Disease 13.2.3. Mucopolysaccharidosis 13.2.3.1. MPS I 13.2.3.2. MPS II (Hunter syndrome) 13.2.3.3. MPS IVA (Morquio syndrome, type A) 13.2.3.4. MPS VI (Maroteaux-Lamy syndrome) 13.2.3.5. MPS VII (Sly syndrome) 13.2.4. Pompe Disease 13.2.5. Lysosomal acid lipase Deficiency 13.2.6. Others 13.3. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2022-2028 13.4. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021 13.4.1. Oral 13.4.2. Injectable 13.5. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028 13.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 13.6.1. Hospital Pharmacies 13.6.2. Specialty Treatment Pharmacies 13.6.3. Retail Pharmacies 13.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028 13.8. Market Attractiveness Analysis 13.8.1. By Therapeutic Condition 13.8.2. By Route of Administration 13.8.3. By Distribution Channel 13.9. Drivers and Restraints: Impact Analysis 13.10. Key Market Participants – Intensity Mapping 14. Middle East and Africa Market Analysis 2013-2021 and Forecast 2022-2028 14.1. Introduction 14.2. Regional Market Trends 14.3. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021 14.3.1. GCC Countries 14.3.2. South Africa 14.3.3. Rest of Middle East and Africa 14.4. Market Size (US$ Mn) Forecast By Country, 2022-2028 14.5. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2021 14.5.1. Fabry Disease 14.5.2. Gaucher Disease 14.5.3. Mucopolysaccharidosis 14.5.3.1. MPS I 14.5.3.2. MPS II (Hunter syndrome) 14.5.3.3. MPS IVA (Morquio syndrome, type A) 14.5.3.4. MPS VI (Maroteaux-Lamy syndrome) 14.5.3.5. MPS VII (Sly syndrome) 14.5.4. Pompe Disease 14.5.5. Lysosomal acid lipase Deficiency 14.5.6. Others 14.6. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2022-2028 14.7. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021 14.7.1. Oral 14.7.2. Injectable 14.8. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028 14.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 14.9.1. Hospital Pharmacies 14.9.2. Specialty Treatment Pharmacies 14.9.3. Retail Pharmacies 14.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028 14.11. Market Attractiveness Analysis 14.11.1. By Country 14.11.2. By Therapeutic Condition 14.11.3. By Route of Administration 14.11.4. By Distribution Channel 14.12. Drivers and Restraints: Impact Analysis 14.13. Key Market Participants – Intensity Mapping 15. Forecast Factors: Relevance and Impact 16. Market Structure Analysis 16.1. Market Structure by Tier 16.2. Market Share Analysis (2017) for Top 10 Players, By Region 17. Competition Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Profitability and Gross Margin Analysis By Competition 17.4. Competitors Deep Dive 17.4.1. Sanofi S.A. (Genzyme Corporation) 17.4.1.1. Overview 17.4.1.2. Product and Application Portfolio 17.4.1.3. Production Footprint 17.4.1.4. Sales Footprint 17.4.1.5. Channel Footprint 17.4.1.6. Strategy 17.4.1.6.1. Marketing Strategy 17.4.1.6.2. Product Strategy 17.4.1.6.3. Channel Strategy 17.4.2. Shire plc. 17.4.2.1. Overview 17.4.2.2. Product and Application Portfolio 17.4.2.3. Production Footprint 17.4.2.4. Sales Footprint 17.4.2.5. Channel Footprint 17.4.2.6. Strategy 17.4.2.6.1. Marketing Strategy 17.4.2.6.2. Product Strategy 17.4.2.6.3. Channel Strategy 17.4.3. Pfizer Inc. 17.4.3.1. Overview 17.4.3.2. Product and Application Portfolio 17.4.3.3. Production Footprint 17.4.3.4. Sales Footprint 17.4.3.5. Channel Footprint 17.4.3.6. Strategy 17.4.3.6.1. Marketing Strategy 17.4.3.6.2. Product Strategy 17.4.3.6.3. Channel Strategy 17.4.4. Alexion Pharmaceuticals, Inc. 17.4.4.1. Overview 17.4.4.2. Product and Application Portfolio 17.4.4.3. Production Footprint 17.4.4.4. Sales Footprint 17.4.4.5. Channel Footprint 17.4.4.6. Strategy 17.4.4.6.1. Marketing Strategy 17.4.4.6.2. Product Strategy 17.4.4.6.3. Channel Strategy 17.4.5. BioMarin Pharmaceutical Inc. 17.4.5.1. Overview 17.4.5.2. Product and Application Portfolio 17.4.5.3. Production Footprint 17.4.5.4. Sales Footprint 17.4.5.5. Channel Footprint 17.4.5.6. Strategy 17.4.5.6.1. Marketing Strategy 17.4.5.6.2. Product Strategy 17.4.5.6.3. Channel Strategy 17.4.6. Ultragenyx Pharmaceutical Inc. 17.4.6.1. Overview 17.4.6.2. Product and Application Portfolio 17.4.6.3. Production Footprint 17.4.6.4. Sales Footprint 17.4.6.5. Channel Footprint 17.4.6.6. Strategy 17.4.6.6.1. Marketing Strategy 17.4.6.6.2. Product Strategy 17.4.6.6.3. Channel Strategy 17.4.7. Johnson & Johnson Services, Inc. 17.4.7.1. Overview 17.4.7.2. Product and Application Portfolio 17.4.7.3. Production Footprint 17.4.7.4. Sales Footprint 17.4.7.5. Channel Footprint 17.4.7.6. Strategy 17.4.7.6.1. Marketing Strategy 17.4.7.6.2. Product Strategy 17.4.7.6.3. Channel Strategy 17.4.8. Allergan plc. 17.4.8.1. Overview 17.4.8.2. Product and Application Portfolio 17.4.8.3. Production Footprint 17.4.8.4. Sales Footprint 17.4.8.5. Channel Footprint 17.4.8.6. Strategy 17.4.8.6.1. Marketing Strategy 17.4.8.6.2. Product Strategy 17.4.8.6.3. Channel Strategy 17.4.9. Leadiant Biosciences, Inc. 17.4.9.1. Overview 17.4.9.2. Product and Application Portfolio 17.4.9.3. Production Footprint 17.4.9.4. Sales Footprint 17.4.9.5. Channel Footprint 17.4.9.6. Strategy 17.4.9.6.1. Marketing Strategy 17.4.9.6.2. Product Strategy 17.4.9.6.3. Channel Strategy 18. Global Market Analysis 2013-2021 and Forecast 2022-2028 By Region 18.1. Introduction / Key Findings 18.2. Historical Market Size (US$ Mn) Analysis By Region 18.2.1. North America 18.2.2. Latin America 18.2.3. Western Europe 18.2.4. Eastern Europe 18.2.5. Asia Pacific Excluding Japan And China 18.2.6. China 18.2.7. Japan 18.2.8. Middle East and Africa 18.3. Market Size (US$ Mn) Forecast By Region 18.4. Market Attractiveness Analysis By Region 19. Global Market Analysis 2013-2021 and Forecast 2022-2028, By Therapeutic Condition 19.1. Introduction/Key Finding 19.2. Historical Market Size (US$ Mn) Analysis By Therapeutic Condition, 2013-2021 19.2.1. Fabry Disease 19.2.2. Gaucher Disease 19.2.3. Mucopolysaccharidosis 19.2.3.1. MPS I 19.2.3.2. MPS II (Hunter syndrome) 19.2.3.3. MPS IVA (Morquio syndrome, type A) 19.2.3.4. MPS VI (Maroteaux-Lamy syndrome) 19.2.3.5. MPS VII (Sly syndrome) 19.2.4. Pompe Disease 19.2.5. Lysosomal acid lipase Deficiency 19.2.6. Others 19.3. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2022-2028 19.4. Market Attractiveness Analysis By Therapeutic Condition 20. Global Market Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration 20.1. Introduction/Key Finding 20.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2013-2021 20.2.1. Oral 20.2.2. Injectable 20.3. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028 20.4. Market Attractiveness Analysis By Route of Administration 21. Global Market Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel 21.1. Introduction/Key Finding 21.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013-2021 21.2.1. Hospital Pharmacies 21.2.2. Specialty Treatment Pharmacies 21.2.3. Retail Pharmacies 21.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028 21.4. Market Attractiveness Analysis By Distribution Channel 22. Global Market Analysis 2013-2021 and Forecast 2022-2028 22.1. Market Value Share Analysis By All Segment 22.2. Y-o-Y Growth Analysis By All Segment 22.3. Absolute $ Opportunity 23. Assumptions and Acronyms Used 24. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 01: Expenditure on Health, (% of GDP), by Country, 2016 - 2021 Table 02: Expenditure on Health, (% of GDP), by Country, 2016 - 2021 Table 03: Comparison of orphan drug regulation across the US, Europe, Japan, Korea, Taiwan and China, 2021 Table 04: Clinical Trials Table 05: Clinical Trials Table 06: Clinical Trials Table 07: Clinical Trials Table 08: Clinical Trials Table 09: Clinical Trials Table 10: Clinical Trials Table 11: Clinical Trials Table 12: Clinical Trials Table 13: Clinical Trials Table 14: Clinical Trials Table 15: Clinical Trials Table 16: Clinical Trials Table 17: Clinical Trials Table 18: North America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country Table 19: North America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Therapeutic Condition Table 20: North America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration Table 21: North America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel Table 22: North America Market Company Intensity Map Table 23: Latin America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country Table 24: Latin America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Therapeutic Condition Table 25: Latin America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration Table 26: Latin America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel Table 27: Latin America Market Company Intensity Map Table 28: Budget Impact Of Orphan Drugs In Western European Countries Table 29: Western Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country Table 30: Western Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Therapeutic Condition Table 31: Western Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration Table 32: Western Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel Table 33: Western Europe Market Company Intensity Map Table 34: Eastern Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country Table 35: Eastern Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Therapeutic Condition Table 36: Eastern Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration Table 37: Eastern Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel Table 38: Eastern Europe Market Company Intensity Map Table 39: National Initiatives to support rare diseases and access to orphan drugs in Southeast Asia, 2016 Table 40: APECJ Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country Table 41: APECJ Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Therapeutic Condition Table 42: APECJ Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration Table 43: APECJ Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel Table 44: APECJ Market Company Intensity Map Table 45: Comparison of China orphan drug policies with other several major countries Table 46: China Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Therapeutic Condition Table 47: China Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration Table 48: China Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel Table 49: China Market Company Intensity Map Table 50: Japan Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Therapeutic Condition Table 51: Japan Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration Table 52: Japan Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel Table 53: Japan Market Company Intensity Map Table 54: MEA Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country Table 55: MEA Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Therapeutic Condition Table 56: MEA Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration Table 57: MEA Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel Table 58: MEA Market Company Intensity Map Table 59: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Region Table 60: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Therapeutic Condition Table 61: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration Table 62: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 01: Market Value Share By Region (2018) Figure 02: Global Healthcare Expenditure in US$ Tn (2013-2021) Figure 03: North America Market Value Share (2021A), By Country Figure 04: North America Market Value Share (2021A), By Therapeutic Condition, Route of Administration and Distribution Channel Figure 05: North America Market Size (US$ Mn) Analysis, 2013-2021 Figure 06: North America Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 07: North America Market Y-o-Y growth (%) Comparison, By Country, 2022-2028 Figure 08: U.S. Market Size (US$ Mn) Analysis, 2013-2021 Figure 09: U.S. Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 10: Canada Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 11: Canada Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 12: Fabry Disease Market Size (US$ Mn) Analysis, 2013-2021 Figure 13: Fabry Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 14: Gaucher Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 15: Gaucher Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 16: Mucopolysaccharidosis Market Size (US$ Mn) Analysis, 2013-2021 Figure 17: Mucopolysaccharidosis Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 18: Pompe Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 19: Pompe Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 20: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Analysis, 2013-2021 Figure 21: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 22: Others Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 23: Others Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 24: North America Market Attractiveness Analysis, By Country Figure 25: North America Market Attractiveness Analysis, By Therapeutic Condition Figure 26: North America Market Attractiveness Analysis, By Route of Administration Figure 27: North America Market Attractiveness Analysis, By Distribution Channel Figure 28: Latin America Market Value Share (2021A), By Country Figure 29: Latin America Market Value Share (2021A), By Therapeutic Condition, Route of Administration and Distribution Channel Figure 30: Latin America Market Size (US$ Mn) Analysis, 2013-2021 Figure 31: Latin America Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 32: Latin America Market Y-o-Y growth (%) Comparison, By Country, 2022-2028 Figure 33: Brazil Market Size (US$ Mn) Analysis, 2013-2021 Figure 34: Brazil Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 35: Mexico Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 36: Mexico Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 37: Rest of Latin America Market Size (US$ Mn) Analysis, 2013-2021 Figure 38: Rest of Latin America Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 39: Fabry Disease Market Size (US$ Mn) Analysis, 2013-2021 Figure 40: Fabry Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 41: Gaucher Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 42: Gaucher Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 43: Mucopolysaccharidosis Market Size (US$ Mn) Analysis, 2013-2021 Figure 44: Mucopolysaccharidosis Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 45: Pompe Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 46: Pompe Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 47: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Analysis, 2013-2021 Figure 48: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 49: Others Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 50: Others Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 51: Latin America Market Attractiveness Analysis, By Country Figure 52: Latin America Market Attractiveness Analysis, By Therapeutic Condition Figure 53: Latin America Market Attractiveness Analysis, By Route of Administration Figure 54: Latin America Market Attractiveness Analysis, By Distribution Channel Figure 55: Western Europe Market Value Share (2021A), By Country Figure 56: Western Europe Market Value Share (2021A), By Therapeutic Condition, Route of Administration and Distribution Channel Figure 57: Western Europe Market Size (US$ Mn) Analysis, 2013-2021 Figure 58: Western Europe Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 59: Western Europe Market Y-o-Y growth (%) Comparison, By Country, 2022-2028 Figure 60: Germany Market Size (US$ Mn) Analysis, 2013-2021 Figure 61: Germany Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 62: U.K. Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 63: U.K. Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 64: France Market Size (US$ Mn) Analysis, 2013-2021 Figure 65: France Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 66: Italy Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 67: Italy Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 68: Spain Market Size (US$ Mn) Analysis, 2013-2021 Figure 69: Spain Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 70: Rest of Western Europe Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 71: Rest of Western Europe Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 72: Fabry Disease Market Size (US$ Mn) Analysis, 2013-2021 Figure 73: Fabry Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 74: Gaucher Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 75: Gaucher Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 76: Mucopolysaccharidosis Market Size (US$ Mn) Analysis, 2013-2021 Figure 77: Mucopolysaccharidosis Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 78: Pompe Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 79: Pompe Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 80: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Analysis, 2013-2021 Figure 81: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 82: Others Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 83: Others Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 84: Western Europe Market Attractiveness Analysis, By Country Figure 85: Western Europe Market Attractiveness Analysis, By Therapeutic Condition Figure 86: Western Europe Market Attractiveness Analysis, By Route of Administration Figure 87: Western Europe Market Attractiveness Analysis, By Distribution Channel Figure 88: Eastern Europe Market Value Share (2021A), By Country Figure 89: Eastern Europe Market Value Share (2021A), By Therapeutic Condition, Route of Administration and Distribution Channel Figure 90: Eastern Europe Market Size (US$ Mn) Analysis, 2013-2021 Figure 91: Eastern Europe Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 92: Eastern Europe Market Y-o-Y growth (%) Comparison, By Country, 2022-2028 Figure 93: Russia Market Size (US$ Mn) Analysis, 2013-2021 Figure 94: Russia Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 95: Poland Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 96: Poland Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 97: Rest of Eastern Europe Market Size (US$ Mn) Analysis, 2013-2021 Figure 98: Rest of Eastern Europe Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 99: Fabry Disease Market Size (US$ Mn) Analysis, 2013-2021 Figure 100: Fabry Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 101: Gaucher Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 102: Gaucher Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 103: Mucopolysaccharidosis Market Size (US$ Mn) Analysis, 2013-2021 Figure 104: Mucopolysaccharidosis Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 105: Pompe Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 106: Pompe Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 107: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Analysis, 2013-2021 Figure 108: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 109: Others Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 110: Others Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 111: Eastern Europe Market Attractiveness Analysis, By Country Figure 112: Eastern Europe Market Attractiveness Analysis, By Therapeutic Condition Figure 113: Eastern Europe Market Attractiveness Analysis, By Route of Administration Figure 114: Eastern Europe Market Attractiveness Analysis, By Distribution Channel Figure 115: APECJ Market Value Share (2021A), By Country Figure 116: APECJ Market Value Share (2021A), By Therapeutic Condition, Route of Administration and Distribution Channel Figure 117: APECJ Market Size (US$ Mn) Analysis, 2013-2021 Figure 118: APECJ Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 119: APECJ Market Y-o-Y growth (%) Comparison, By Country, 2022-2028 Figure 120: India Market Size (US$ Mn) Analysis, 2013-2021 Figure 121: India Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 122: Australia & NZ Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 123: Australia & NZ Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 124: ASEAN Market Size (US$ Mn) Analysis, 2013-2021 Figure 125: ASEAN Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 126: Rest of APECJ Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 127: Rest of APECJ Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 128: Fabry Disease Market Size (US$ Mn) Analysis, 2013-2021 Figure 129: Fabry Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 130: Gaucher Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 131: Gaucher Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 132: Mucopolysaccharidosis Market Size (US$ Mn) Analysis, 2013-2021 Figure 133: Mucopolysaccharidosis Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 134: Pompe Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 135: Pompe Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 136: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Analysis, 2013-2021 Figure 137: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 138: Others Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 139: Others Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 140: APECJ Market Attractiveness Analysis, By Country Figure 141: APECJ Market Attractiveness Analysis, By Therapeutic Condition Figure 142: APECJ Market Attractiveness Analysis, By Route of Administration Figure 143: APECJ Market Attractiveness Analysis, By Distribution Channel Figure 144: China Market Value Share (2021A), By Therapeutic Condition, Route of Administration and Distribution Channel Figure 145: China Market Size (US$ Mn) Analysis, 2013-2021 Figure 146: China Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 147: Fabry Disease Market Size (US$ Mn) Analysis, 2013-2021 Figure 148: Fabry Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 149: Gaucher Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 150: Gaucher Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 151: Mucopolysaccharidosis Market Size (US$ Mn) Analysis, 2013-2021 Figure 152: Mucopolysaccharidosis Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 153: Pompe Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 154: Pompe Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 155: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Analysis, 2013-2021 Figure 156: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 157: Others Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 158: Others Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 159: China Market Attractiveness Analysis, By Therapeutic Condition Figure 160: China Market Attractiveness Analysis, By Route of Administration Figure 161: China Market Attractiveness Analysis, By Distribution Channel Figure 162: Japan Market Value Share (2021A), By Therapeutic Condition, Route of Administration and Distribution Channel Figure 163: Japan Market Size (US$ Mn) Analysis, 2013-2021 Figure 164: Japan Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 165: Fabry Disease Market Size (US$ Mn) Analysis, 2013-2021 Figure 166: Fabry Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 167: Gaucher Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 168: Gaucher Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 169: Mucopolysaccharidosis Market Size (US$ Mn) Analysis, 2013-2021 Figure 170: Mucopolysaccharidosis Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 171: Pompe Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 172: Pompe Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 173: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Analysis, 2013-2021 Figure 174: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 175: Others Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 176: Others Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 177: Japan Market Attractiveness Analysis, By Therapeutic Condition Figure 178: Japan Market Attractiveness Analysis, By Route of Administration Figure 179: Japan Market Attractiveness Analysis, By Distribution Channel Figure 180: MEA Market Value Share (2021A), By Country Figure 181: MEA Market Value Share (2021A), By Therapeutic Condition, Route of Administration and Distribution Channel Figure 182: MEA Market Size (US$ Mn) Analysis, 2013-2021 Figure 183: MEA Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 184: MEA Market Y-o-Y growth (%) Comparison, By Country, 2022-2028 Figure 185: GCC Countries Market Size (US$ Mn) Analysis, 2013-2021 Figure 186: GCC Countries Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 187: South Africa & NZ Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 188: South Africa Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 189: Rest of MEA Market Size (US$ Mn) Analysis, 2013-2021 Figure 190: Rest of MEA Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 191: Fabry Disease Market Size (US$ Mn) Analysis, 2013-2021 Figure 192: Fabry Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 193: Gaucher Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 194: Gaucher Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 195: Mucopolysaccharidosis Market Size (US$ Mn) Analysis, 2013-2021 Figure 196: Mucopolysaccharidosis Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 197: Pompe Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 198: Pompe Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 199: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Analysis, 2013-2021 Figure 200: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 201: Others Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028 Figure 202: Others Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028 Figure 203: MEA Market Attractiveness Analysis, By Country Figure 204: MEA Market Attractiveness Analysis, By Therapeutic Condition Figure 205: MEA Market Attractiveness Analysis, By Route of Administration Figure 206: MEA Market Attractiveness Analysis, By Distribution Channel Figure 207: Revenue Contribution by Tier Type (2021) Figure 208: Global Market Share (%) Analysis Figure 209: Global Market Attractiveness Analysis, By Region Figure 210: Global Market Attractiveness Analysis, By Therapeutic Condition Figure 211: Global Market Attractiveness Analysis, By Route of Administration Figure 212: Global Market Attractiveness Analysis, By Distribution Channel Figure 213: Global Market Size and Y-o-Y, 2013-2021 Figure 214: Global Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028 Figure 215: Global Market Absolute $ Opportunity, 2013–2028
Recommendations
Explore Healthcare Insights
View Reports
